Mr Kenneth A Janes, MD | |
190 Groton Road, Suite 210, Ayer, MA 01432 | |
(978) 772-6265 | |
(978) 772-5348 |
Full Name | Mr Kenneth A Janes |
---|---|
Gender | Male |
Speciality | Surgery |
Location | 190 Groton Road, Ayer, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134177546 | NPI | - | NPPES |
2031132 | Medicaid | MA | |
B1817002 | Other | MA | PTAN 41 |
708834 | Other | TUFTS | |
801509 | Other | HARVARD PILGRIM | |
B1817001 | Other | MA | PTAN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 31891 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Kenneth A Janes, MD 190 Groton Road, Suite 210, Ayer, MA 01432 Ph: (978) 772-6265 | Mr Kenneth A Janes, MD 190 Groton Road, Suite 210, Ayer, MA 01432 Ph: (978) 772-6265 |
News Archive
Phytel today launched the next generation of automated care management solutions with its integrated Atmosphereâ„¢ platform, which enables providers to better manage quality and proactively improve chronic and preventive care across their populations. These scalable, Software-as-a-Service automation tools together comprise the first comprehensive, integrated population health management solution designed for providers.
A report publicly released today by the Institute for Good Medicine at the Pennsylvania Medical Society suggests demand for charitable care provided by physicians increased significantly in the past year, and that their ability to meet the demand may be unsustainable.
Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.
Researchers at Pulmonary Associates today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally invasive option for those suffering with advanced widespread emphysema.
BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema.
› Verified 8 days ago
Jeffrey P Arpin, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 190 Groton Rd, Ste 210, Ayer, MA 01432 Phone: 978-772-6265 Fax: 978-772-5348 |